Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944749 | 0.95 | HPGD (0.49) | ALDH1A1NPSR1ALDH1A2HPGDKDM4E | |
| SCHEMBL4937656 | 0.94 | ALDH1A1 (0.52) | ALDH1A1NPSR1HPGDKDM4EMAPT | |
| SCHEMBL4940658 | 0.93 | NPSR1 (0.49) | ALDH1A1NPSR1HPGDMAPTL3MBTL1 | |
| SCHEMBL4946428 | 0.93 | NPSR1 (0.52) | ALDH1A1NPSR1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL4940554 | 0.92 | ALDH1A1 (0.47) | ALDH1A1NPSR1HPGDMAPTTP53 | |
| SCHEMBL4937715 | 0.91 | ALDH1A1 (0.53) | ALDH1A1NPSR1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL4945464 | 0.91 | ALDH1A1 (0.47) | ALDH1A1NPSR1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL4944377 | 0.90 | ALDH1A1 (0.49) | ALDH1A1NPSR1HPGDKDM4EMAPT | |
| SCHEMBL4943640 | 0.89 | ALDH1A1 (0.51) | ALDH1A1NPSR1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL4944436 | 0.89 | HPGD (0.50) | ALDH1A1NPSR1HPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | claimed |
| EP-1458381-B1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-30 | — | — | EP | claimed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | claimed |
| EP-1458381-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053437-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | claimed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187275-A1 | Triazoles as oxytocin antagonists | OXTR, AVPR2, AVPR1B | ALDH1A1 4091/4885NPSR1 17/4885ALDH1A2 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.